Lineage Cell Therapeutics, Inc. (LCTX) Form 10-Q Quarterly Reports
Lineage Cell Therapeutics, Inc. (LCTX) is a publicly traded company on the NYSE, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: LCTX
CIK: 876343
Exchange: NYSE
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 12/31
State: CA
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Baker Tilly US, LLP
Auditor SinceSince 12/31/2025 12:00:00 AM
Lead Engagement PartnerCarisa Wisniewski
Audit LocationSan Diego, California, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 10-Q | 2026-08-06 | 2026-06-30 | 10-Q | 0001193125-26-338064 | View SEC Doc Filr Page |
| 8-K | 2026-08-06 | 2026-08-06 | 8-K | 0001193125-26-338020 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-07-29 | — | SCHEDULE 13G Filing | 0002012383-26-002817 | View SEC Doc Filr Page |
| 4 | 2026-07-02 | 2026-07-01 | 4 Filing | 0000919574-26-004259 | View SEC Doc Filr Page |
| 4 | 2026-07-02 | 2026-07-01 | 4 | 0001193125-26-294873 | View SEC Doc Filr Page |
| 4 | 2026-07-02 | 2026-07-01 | 4 | 0001193125-26-294871 | View SEC Doc Filr Page |
| 4 | 2026-07-02 | 2026-07-01 | 4 | 0001193125-26-294860 | View SEC Doc Filr Page |
| 4 | 2026-07-02 | 2026-07-01 | 4 | 0001193125-26-294859 | View SEC Doc Filr Page |
| 4 | 2026-07-02 | 2026-07-01 | 4 | 0001193125-26-294852 | View SEC Doc Filr Page |
| 8-K | 2026-06-12 | 2026-06-09 | 8-K | 0001193125-26-269557 | View SEC Doc Filr Page |
| 10-Q | 2026-05-12 | 2026-03-31 | 10-Q | 0001193125-26-219479 | View SEC Doc Filr Page |
| 8-K | 2026-05-12 | 2026-05-12 | 8-K | 0001193125-26-219421 | View SEC Doc Filr Page |
| ARS | 2026-04-29 | 2025-12-31 | ARS | 0001193125-26-191714 | View SEC Doc Filr Page |
| DEFA14A | 2026-04-29 | — | DEFA14A | 0001193125-26-191616 | View SEC Doc Filr Page |
| DEF 14A | 2026-04-29 | 2026-04-29 | DEF 14A | 0001193125-26-191556 | View SEC Doc Filr Page |
| EFFECT | 2026-03-23 | — | EFFECT Filing | 9999999995-26-000908 | View SEC Doc Filr Page |
| CORRESP | 2026-03-19 | — | CORRESP Filing | 0001193125-26-116059 | View SEC Doc Filr Page |
| UPLOAD | 2026-03-16 | — | UPLOAD Filing | 0000000000-26-002663 | View SEC Doc Filr Page |
| 4 | 2026-03-12 | 2026-03-12 | 4 | 0001193125-26-104106 | View SEC Doc Filr Page |
| S-3 | 2026-03-11 | — | S-3 | 0001193125-26-101168 | View SEC Doc Filr Page |
| 8-K | 2026-03-11 | 2026-03-11 | 8-K | 0001193125-26-101167 | View SEC Doc Filr Page |
| 424B5 | 2026-03-11 | — | 424B5 | 0001193125-26-101166 | View SEC Doc Filr Page |
| 4 | 2026-03-06 | 2026-03-05 | 4 | 0001193125-26-097185 | View SEC Doc Filr Page |
| 4 | 2026-03-06 | 2026-03-05 | 4 | 0001193125-26-097184 | View SEC Doc Filr Page |
| 4 | 2026-03-06 | 2026-03-05 | 4 | 0001193125-26-097181 | View SEC Doc Filr Page |